Astrazeneca PLC (AZN) Stock Rating Reaffirmed by Shore Capital
Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating reissued by investment analysts at Shore Capital in a research note issued on Thursday.
Several other analysts also recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Monday, August 8th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, August 10th. TheStreet raised Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Friday, July 22nd. Bank of America Corp. reaffirmed a “buy” rating and set a $36.65 price objective on shares of Astrazeneca PLC in a research note on Monday, July 18th. Finally, Argus raised Astrazeneca PLC from a “hold” rating to a “buy” rating and set a $38.00 price objective for the company in a research note on Monday, August 29th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $37.61.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 27.98 on Thursday. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The stock has a 50 day moving average price of $30.57 and a 200-day moving average price of $30.84. The firm has a market capitalization of $70.79 billion, a price-to-earnings ratio of 31.98 and a beta of 0.83.
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, November 10th. The company reported $1.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 31.30% and a net margin of 10.35%. The business earned $5.70 billion during the quarter, compared to the consensus estimate of $5.95 billion. During the same period in the previous year, the business earned $1.03 EPS. The business’s quarterly revenue was down 2.6% on a year-over-year basis. On average, analysts anticipate that Astrazeneca PLC will post $2.99 EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. RDL Financial Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth $532,000. Ngam Advisors L.P. raised its position in shares of Astrazeneca PLC by 72.4% in the second quarter. Ngam Advisors L.P. now owns 440,868 shares of the company’s stock worth $13,310,000 after buying an additional 185,089 shares in the last quarter. Boyer & Corporon Wealth Management LLC raised its position in shares of Astrazeneca PLC by 1.6% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 28,222 shares of the company’s stock worth $852,000 after buying an additional 434 shares in the last quarter. Becker Capital Management Inc. acquired a new position in shares of Astrazeneca PLC during the second quarter worth $35,701,000. Finally, O Shaughnessy Asset Management LLC acquired a new position in shares of Astrazeneca PLC during the second quarter worth $4,535,000. 11.58% of the stock is currently owned by institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.